Search research articles
Contact Us
Filters
Showing results (41-50 of 129) with videos related to
Page
of 13
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 22, 2025
Brief Report: Alectinib with salvage platinum-taxane chemotherapy in a pregnant woman with ALK-rearranged NSCLC and rapid disease progression followed by a successful pregnancy
Richard Pham, Daniel Garama, Atul Malhotra, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 27, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts
Nancee Pronsati, Geoffrey Liu, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Oliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
JTO Clinical and Research Reports
|
February 2, 2026
Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)
Grace Chazan, Marliese Alexander, Fanny Franchini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.
Cancer Research and Treatment
|
July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
JTO Clinical and Research Reports
|
August 11, 2025
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis
Jay M Lee, Alessandro Brunelli, Amy L Cummings, et al.
JTO Clinical and Research Reports
|
April 20, 2023
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
Marliese Alexander, Joe Wei, Sagun Parakh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung Cancer
Maurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 129) with videos related to
Sort By:
Page
of 13
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 24, 2024
Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report
Sai-Hong Ignatius Ou, Benjamin J Solomon, Benjamin Besse, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 22, 2025
Brief Report: Alectinib with salvage platinum-taxane chemotherapy in a pregnant woman with ALK-rearranged NSCLC and rapid disease progression followed by a successful pregnancy
Richard Pham, Daniel Garama, Atul Malhotra, et al.
Lung Cancer (Amsterdam, Netherlands)
|
July 27, 2025
Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts
Nancee Pronsati, Geoffrey Liu, Todd M Bauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2025
Selpercatinib in <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
Oliver Gautschi, Keunchil Park, Benjamin J Solomon, et al.
JTO Clinical and Research Reports
|
February 2, 2026
Treatment Patterns, Prognostic Factors and Survival for ALK-Positive Advanced NSCLC In Australia: Results From the Australasian Thoracic Cancers Longitudinal Cohort Study and Biobank (AURORA)
Grace Chazan, Marliese Alexander, Fanny Franchini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 17, 2018
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer
Benjamin J Solomon, Dong-Wan Kim, Yi-Long Wu, et al.
Cancer Research and Treatment
|
July 14, 2017
Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
Makoto Nishio, Dong-Wan Kim, Yi-Long Wu, et al.
JTO Clinical and Research Reports
|
August 11, 2025
Phase 3 Trials of Neoadjuvant, Perioperative, and Adjuvant Chemoimmunotherapy for Resectable, Early-Stage NSCLC: Comprehensive Review and Detailed Analysis
Jay M Lee, Alessandro Brunelli, Amy L Cummings, et al.
JTO Clinical and Research Reports
|
April 20, 2023
LOREALAUS: LOrlatinib REAL-World AUStralian Experience in Advanced ALK-Rearranged NSCLC
Marliese Alexander, Joe Wei, Sagun Parakh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2024
CNS Protective Effect of Selpercatinib in First-Line <i>RET</i> Fusion-Positive Advanced Non-Small Cell Lung Cancer
Maurice Pérol, Benjamin J Solomon, Koichi Goto, et al.
Page
of 13